Medicure Inc. Reveals Financial Results for 2024

Medicure Inc. has reported its financial performance for the year ending December 31, 2024. The company recorded a total net revenue of CAD $21.9 million, a slight increase from the previous year's CAD $21.7 million. However, the company's adjusted EBITDA turned negative at CAD $437,000, contrasting with a positive CAD $1.9 million in 2023.

The AGGRASTAT® product sales saw a decline to CAD $8.1 million from CAD $9.7 million in 2023. The decrease is attributed to reduced sales volume and market competition. Conversely, the Marley Drug business reported higher revenues, totaling CAD $10.8 million, an increase from CAD $9.6 million the previous year.

ZYPITAMAG® sales rose due to volume increases through drug wholesalers, contributing CAD $6.2 million compared to CAD $5.0 million in 2023. The net loss for the year was CAD $1.0 million, slightly higher than 2023's CAD $922,000, primarily due to increased costs and expenses despite revenue growth in ZYPITAMAG® and Marley Drug.